Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care System

Clinical Landscape of Epidemiology and Assessment of Results in Hypertension

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07361276

Acronym

CLEAR-HTN

Enrollment

15000

Registered

2026-01-23

Start date

2026-03-31

Completion date

2026-09-30

Last updated

2026-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Blood Pressure, High

Brief summary

Detailed description

This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS). The retrospective cohort design allows for efficient use of existing clinical data to evaluate real-world practice against national guideline recommendations. The primary outcomes relate to treatment decisions and delays rather than interventional effects; therefore, an observational design is methodologically appropriate and ethically preferable. The study will be conducted across 05 Brazilian municipalities participating in the epHealth Primary Care Solutions platform. These municipalities span multiple regions and reflect heterogeneity in socio-demographic context, healthcare infrastructure, and epidemiological profiles.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥18 years at the time of Hypertension diagnosis * Hypertension diagnosis as retrieved from registered ICD codes or CIAP Codes (primary care codes) in the EMR , OR At least two blood pressure measurements ≥140/90 mmHg during the study period. The blood measurements should be consecutive and obtained within a 30 days period. * Continuous follow-up in the same municipality for at least 6 months after index measurement. * Availability of structured EMR data including clinical encounters, diagnoses, and prescriptions

Exclusion criteria

\- Patients with incomplete data or not traceable in the registration systems

Design outcomes

Primary

Measure	Time frame	Description
Uncontrolled blood pressure	through study completion, an average of 1 year	Proportion of patients with uncontrolled blood pressure (BP ≥ 140/90 mmHg) who did not receive treatment intensification within 3 months of a recorded elevated BP.

Secondary

Measure	Time frame	Description
Antihypertensive treatment	through study completion, an average of 1 year	Proportions receiving monotherapy vs. combination therapy; distribution by pharmacologic class.
Risk stratification	through study completion, an average of 1 year	Likelihood of treatment escalation stratified by low/moderate vs. high/very high CV risk.

Countries

Brazil

Contacts

CONTACTAstraZeneca Clinical Study Information Center

information.center@astrazeneca.com1-877-240-9479

PRINCIPAL_INVESTIGATORJulia Machline Carrion, Medical

EpHealth Soluções em Tecnologia da Informação Ltda

Outcome results